Switch to optionsXpress for advanced derivatives trading & earn 50 commission-free trades.
SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator joboggi, zoomboom, Rosym
Search This Board:
Last Post: 3/30/2015 5:07:20 PM - Followers: 720 - Board type: Free - Posts Today: 23

Amarantus BioScience Holdings, Inc.

   Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
   The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
   The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
   The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
 For further information, please visit www.Amarantus.comor connect with the company in FacebookTwitter, LinkedIn & Google+


Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the Start of a Phase 2b Program of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
March 26, 2015
Amarantus Shareholder Update: Fundamental Progress on the Pipeline and Strategy Continues
Thursday, March 26th, 2015 
Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015

March 23, 2015
A Deep Look At Amarantus’ Phase 2b Eltoprazine For Parkinson’s Dyskinesia
By Jason NapodanoWednesday, March 4, 2015
Large Pharmaceuticals and Biotech Startups Partnering To Develop Alzheimer’s Treatments
February 26, 2015
Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test(R) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
"The LymPro® Assay: A Biomarker For Alzheimer's Disease Using Blood Samples From Clinically Diagnosed Alzheimer's Disease And Cognitively Intact Subjects," was accepted for poster presentation at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders  (AD/PDTM 2015) being held March 18-22, 2015, in Nice, France.
Feb. 23, 2015
Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test(R) With Anavex Life Sciences Corp.
Feb. 18, 2015
Diagnostic and therapeutic products with potential for orphan drug designations in the areas of neurology, psychiatry, ophthalmology and regenerative medicine  -  17th Annual BIO CEO & Investor Conference
Feb. 10, 2015

New therapeutic principle for Parkinsonian dyskinesia shows clinical effect
Feb. 10, 2015
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia -  Eltoprazine is a small-molecule 5-HT1A/1B serotonin receptor agonist, investigational drug candidate, with a well-established safety profile. A Phase 2a dose-finding study was conducted with eltoprazine to determine its effect against levodopa-induced dyskinesia, in patients with Parkinson's disease (PD). The double-blind, randomized, placebo-controlled clinical study was led by Professor Per Svenningsson, M.D., Ph.D., Centre for Molecular Medicine, Karolinska Institutet, Professor Anders Björklund, Ph.D., Faculty of Medicine at Lund University, and Professor Håkan Widner, M.D., Ph.D., Faculty of Medicine at Lund University. The study was partially supported by a grant from Michael J. Fox Foundation for Parkinson's Research.
Feb. 10, 2015
New Test Claims It Can Tell If You Will Develop Alzheimer's... But Do You Want To Know?
Feb. 06, 2015
Amarantus Creates Alzheimer`s Disease Diagnostics Scientific Advisory Board
Congressman Fattah Meets with Biotech Company on Brain Research Efforts; Announced as Co-Chair of Alzheimer`s Caucus
February 03/15
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
Jan. 15, 2015

Developing an Accurate Test for Multiple Sclerosis

 Mar 5, 2014


December 12, 2014
SNNLive - Amarantus BioScience Holdings, Inc.


Oct. 19, 2014
Amarantus BioSciences



Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva


Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc

408-737-2734 x101

Gerald's email address


VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols

Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179



  Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen  cool
smiley   Gerald E. Commissiong  -  We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above and will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.
Gerald E. Commissiong, President & CEO, will be presenting at the Neurotech Investing and Partnering Conference being held April 7-8, 2015 at the Hotel Nikko in San Francisco, CA. Mr. Commissiong will discuss the Company's proprietary Alzheimer's blood diagnostic LymPro Test®and the strategic plans for Amarantus Diagnostics on Tuesday, April 7, 2015, from 10:30-11:30 a.m. Pacific Daylight
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AMBS News: Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the... 03/26/2015 10:00:00 AM
AMBS News: Amended Current Report Filing (8-k/a) 03/25/2015 06:02:42 AM
AMBS News: Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015 03/23/2015 08:05:00 AM
AMBS News: Current Report Filing (8-k) 03/03/2015 05:30:03 PM
AMBS News: Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 03/03/2015 09:35:00 AM
#110746  Sticky Note Jason Napodano - 15 Biotech Names For 2015 Rosym 01/05/15 04:13:55 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#112328   Another rough day today. Lots of dumping. Deputy123 03/30/15 05:07:20 PM
#112326   1.4m shares traded after hours...boy the volume kills Alapis 03/30/15 04:18:19 PM
#112325   I truly hope that we will get the Alapis 03/30/15 04:11:14 PM
#112324   1.46 million share t trade, a buy at .052 jjr04001 03/30/15 04:05:17 PM
#112323   Scroll down a day or two and you'll jjr04001 03/30/15 04:03:53 PM
#112320   $180K buy a few min ago drog68 03/30/15 03:01:17 PM
#112319   TOXIC Financer DOMINION adds nearly 5% to ownership. Sgt. Pepper 03/30/15 02:57:57 PM
#112318   TOXIC FINANCER Dominion is the LARGEST shareholder Sgt. Pepper 03/30/15 02:57:45 PM
#112317   150,000,000 Share DILUTION Coming Sgt. Pepper 03/30/15 02:57:33 PM
#112316   what bounce? der_deutschetrader 03/30/15 02:24:20 PM
#112315   Pattern usually repeats. Bounce... dshade 03/30/15 12:48:35 PM
#112314   2nd bounce coming. Jumping back in. jjr04001 03/30/15 12:23:09 PM
#112313   Interesting also...no mention of the already grsnted ODD Videoone 03/30/15 11:51:52 AM
#112312   Plus this recent IND is bring back attention dshade 03/30/15 09:37:46 AM
#112311   Quiet period MUST have been for a good Alapis 03/30/15 09:37:41 AM
#112310   Still say strength of Board and new hires dshade 03/30/15 09:18:59 AM
#112307   75% of $7.5-Mil. in NJ Tax credits is JPetroInc 03/30/15 06:57:29 AM
#112306   Seems As if additional MANF patents have been zoomboom 03/30/15 12:26:40 AM
#112305   No doubt it is best hire. Just look GS1 03/29/15 11:55:14 PM
#112304   Everyone is promising to fix the worlds Alzheimers Salexander1 03/29/15 07:41:35 AM
#112303   Lympro Status GS1 03/29/15 07:30:48 AM
#112302   Thats Great, great Find !! now AMBS can zoomboom 03/29/15 07:11:55 AM
#112301   http://www.courierpostonline.com/story/news/local/south-jersey/2015/03/28/rowan- joboggi 03/28/15 11:55:34 PM
#112300   it will be impressive when sustainable revenue is JPetroInc 03/28/15 03:28:59 PM
#112299   More Deals.... GS1 03/28/15 02:39:10 PM
#112298   All fair game....:-) GS1 03/28/15 10:03:23 AM
#112296   Just impressive how AMBS CEO Gerald Commissiong continues zoomboom 03/28/15 09:18:01 AM
#112295   Ravi Kiron, Ph.D., a co-founder in C2N and GS1 03/28/15 09:17:30 AM
#112294   I sincerely doubt Rovi Kiron was hired as JPetroInc 03/28/15 08:36:08 AM
#112293   Yep. Good hire by AMBS zoomboom 03/28/15 07:58:42 AM
#112292   Kinemed Biomarker deal with GlaxoSmithKline GS1 03/28/15 07:46:33 AM
#112291   Ravi Kiron's Kinemed Deal With MedImmune (Research Arm GS1 03/28/15 05:02:37 AM
#112290   Retaining Ravi Kiron, Ph.D., a co-founder in C2N GS1 03/28/15 04:54:14 AM
#112289   Glwt shamalam 03/27/15 10:44:45 PM
#112288   For someone who doesnt have anything good to Salexander1 03/27/15 05:48:20 PM
#112287   What is actually funded right now and moving joboggi 03/27/15 12:28:38 PM
#112286   and they certainly used Lympro in their study, joboggi 03/27/15 12:24:37 PM
#112285   The better way to look at it is joboggi 03/27/15 12:21:49 PM
#112284   Yup and question is if the cat is JMali83 03/27/15 09:12:32 AM
#112283   true that...BP will be watchin AMBS more closely Alapis 03/27/15 08:54:43 AM
#112282   IND is important step. More to come. dshade 03/27/15 08:51:26 AM
#112281   One Mind, NIH, NFL, MJFF JPetroInc 03/27/15 08:07:17 AM
#112280   I met some Parkinson's and Brain Injury funding dshade 03/27/15 07:43:36 AM
#112279   "The Company will begin to map out a JPetroInc 03/27/15 05:32:56 AM
#112278   There is real support at 0.001! sante1 03/27/15 05:21:03 AM
#112277   you may remember that I first said that joboggi 03/27/15 03:56:06 AM
#112276   There is real support at three cents and percival77 03/26/15 11:48:59 PM
#112275   Yep. Your post made me look back at zoomboom 03/26/15 11:44:08 PM
#112274   http://www.bloomberg.com/news/articles/2015-03-24/alzheimer-s-debate-revived-eve 68-Tele 03/26/15 11:40:23 PM
#112273   Oldies but goody SAN FRANCISCO and GENEVA, July zoomboom 03/26/15 11:00:57 PM